Health Care & Life Sciences » Pharmaceuticals | Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
33,879.00
50,157.00
109,925.00
146,017.00
165,083.00
193,118
Cost of Goods Sold (COGS) incl. D&A
1,927.00
4,367.00
36,434.00
35,645.00
19,598.00
22,035
Gross Income
31,952.00
45,790.00
73,491.00
110,372.00
145,485.00
171,083
SG&A Expense
52,352.00
102,744.00
113,676.00
128,943.00
162,388.00
149,345
EBIT
20,400.00
56,954.00
40,185.00
18,571.00
16,903.00
21,738
Unusual Expense
-
77,016.00
-
-
-
-
Non Operating Income/Expense
145.00
124.00
320.00
665.00
1,472.00
3,608
Pretax Income
20,255.00
20,186.00
39,865.00
17,906.00
15,431.00
25,346
Income Tax
-
-
-
104.00
136.00
138
Consolidated Net Income
20,255.00
20,186.00
39,865.00
18,010.00
15,567.00
25,208
Net Income
20,255.00
20,186.00
39,865.00
18,010.00
15,567.00
25,208
Net Income After Extraordinaries
20,255.00
20,186.00
39,865.00
18,010.00
15,567.00
25,208
Net Income Available to Common
20,255.00
20,186.00
39,865.00
18,010.00
15,567.00
25,208
EPS (Basic)
0.67
0.55
0.94
0.41
0.35
0.48
Basic Shares Outstanding
30,351.40
34,774.20
42,250.30
43,449.40
44,735.10
50,859.90
EPS (Diluted)
0.67
0.55
0.94
0.41
0.35
0.48
Diluted Shares Outstanding
30,351.40
36,686.70
42,250.30
43,449.40
44,735.10
53,045.30
EBITDA
18,473.00
54,170.00
26,631.00
6,703.00
13,919.00
24,694

About Vanda Pharmaceuticals

View Profile
Address
2200 Pennsylvania Avenue NW
Washington District of Columbia 20037
United States
Employees -
Website http://www.vandapharma.com
Updated 07/08/2019
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.